Securing Both Germanium-68 Production and Adsorption Material Technologies... "Demonstrating the Potential for Full-Cycle Self-Reliance"

The Ministry of Science and ICT announced on February 13 that the Korea Atomic Energy Research Institute has secured all the core element technologies for a Gallium-68 (Ga-68) generator, laying the groundwork for localization of radiopharmaceuticals used to diagnose intractable cancers. This achievement targets both patient treatment safety and industrial competitiveness, as it means that equipment and raw material technologies, which had previously depended on imports, have now been secured domestically.

Scanning electron microscope (SEM) image showing the morphology and surface of the core material of a Gallium-68 generator. Provided by the research team.

Scanning electron microscope (SEM) image showing the morphology and surface of the core material of a Gallium-68 generator. Provided by the research team.

View original image

Ga-68 is a positron emission tomography (PET) radioisotope used to diagnose intractable cancers such as prostate cancer and neuroendocrine tumors. Because it has a short half-life of 68 minutes, it is difficult to store on its own and must be frequently eluted from a "generator" that adsorbs Germanium-68 (Ge-68). However, South Korea has so far lacked both Ge-68 production and high-performance adsorption material technologies, and has therefore relied entirely on imports.


The Advanced Radiation Technology Institute of the Korea Atomic Energy Research Institute, having secured Ge-68 production technology based on a 30 MeV cyclotron, also succeeded in developing an adsorption material that stably binds germanium while selectively separating and eluting gallium-68. The research team implemented a durable, micro-particle material using the natural polymer chitosan and a metal oxide precursor.


Evaluation results showed that the elution efficiency of gallium-68 is about 70%, a level comparable to leading products in the global market. A single elution can produce enough radiopharmaceuticals for six patients, and the usable period is about twice as long as existing foreign-made products, at around one year, which is expected to improve operational efficiency in clinical settings.

A view of the completed system configuration for preclinical evaluation after installing the core material column of a Gallium-68 generator at the hospital. Photo provided by the research team.

A view of the completed system configuration for preclinical evaluation after installing the core material column of a Gallium-68 generator at the hospital. Photo provided by the research team.

View original image

The research team, in collaboration with Seoul National University Bundang Hospital, conducted preclinical tests of a radiopharmaceutical for prostate cancer diagnosis and successfully obtained tumor images, and the related technologies have been granted patents both in Korea and overseas. The team plans to promote technology transfer to domestic radiopharmaceutical companies in the future.


Park Junghoon, Head of the Cyclotron Application Research Division at the Advanced Radiation Technology Institute of the Korea Atomic Energy Research Institute, said, "We have secured all the element technologies needed to develop a cyclotron-based Ga-68 generator," adding, "Once we further advance our AI-based autonomous operation and manufacturing system and mass-produce germanium-68, we will be able to reliably meet domestic demand."



Oh Daehyun, Director-General for Future Strategic Technology Policy at the Ministry of Science and ICT, said, "This is a case that demonstrates our ability to carry out the entire cycle with domestic technology, from radioisotope production and drug development to the diagnosis and treatment of intractable cancers," and added, "Through follow-up projects, we will continue to support core technology R&D and its linkage to industry."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing